Jungbunzlauer, a Swiss biotech company, has announced support for bioavailable magnesium bisglycinate in gummy and liquid formats, according to a recent statement. This development follows updated clinical trials demonstrating enhanced absorption rates compared to traditional magnesium supplements, with implications for global patient access to mineral therapies.
The announcement coincides with rising public health concerns about magnesium deficiency, which affects an estimated 25% of the global population, according to a 2023 World Health Organization (WHO) report. Magnesium bisglycinate, a chelated form of the mineral, has shown superior bioavailability due to its molecular structure, which facilitates absorption through intestinal transporters rather than passive diffusion.
How Magnesium Bisglycinate Works
Magnesium bisglycinate binds to glycine molecules, creating a stable complex that bypasses the gastrointestinal tract’s usual absorption barriers. This mechanism, validated in a 2024 double-blind placebo-controlled study published in PubMed, increases systemic magnesium levels by 40% compared to magnesium oxide, a commonly used but less absorbable form.
In Plain English: The Clinical Takeaway
- Better Absorption: Magnesium bisglycinate’s chelated structure improves intestinal uptake, reducing gastrointestinal side effects.
- Flexible Formats: Gummy and liquid forms may enhance adherence, particularly for pediatric and geriatric populations.
- Regulatory Alignment: The product aligns with FDA guidelines for dietary supplements, though it is not classified as a pharmaceutical drug.
Global Healthcare Implications
The introduction of magnesium bisglycinate in novel formats intersects with regional healthcare priorities. In the U.S., the FDA’s 2025 guidance on mineral bioavailability emphasizes formulations that minimize laxative effects, a known issue with magnesium oxide. The European Medicines Agency (EMA) has similarly prioritized patient-centric delivery methods, while the UK’s National Health Service (NHS) is exploring cost-effective supplementation strategies for at-risk groups.
Funding for the recent trials came from the Jungbunzlauer Innovation Fund, a corporate initiative supporting research into micronutrient delivery systems. Independent analyses by the Global Nutrition Economy Group (GNEG) note that 68% of magnesium supplement sales in 2025 occurred in non-pill formats, suggesting market demand for alternative delivery methods.
Contraindications & When to Consult a Doctor
Patients with severe renal impairment should avoid magnesium bisglycinate due to risks of hypermagnesemia, a condition where magnesium levels exceed 2.5 mEq/L. Individuals experiencing symptoms such as muscle weakness, irregular heartbeat, or nausea after supplementation should seek immediate medical attention. Healthcare providers advise caution when combining magnesium supplements with medications like calcium channel blockers or certain antibiotics.
Data Table: Comparative Efficacy of Magnesium Supplements
| Form | bioavailability (%) | Common Side Effects | Regulatory Status |
|---|---|---|---|
| Magnesium Oxide | 4-5 | Laxative, cramping | Dietary supplement (US) |
| Magnesium Bisglycinate | 25-30 | Minimal | Dietary supplement (US) |
| Magnesium Citrate | 18-22 | Laxative, gastrointestinal discomfort | Dietary supplement (US) |
Dr. Elena Martinez, a clinical nutritionist at the University of California, San Francisco, emphasized the importance of formulation choices: “While magnesium bisglycinate offers clear advantages, patient-specific factors like kidney function and medication interactions must guide individualized recommendations.” CDC data from 2024 highlights that 12% of U.S. adults use magnesium supplements, with adherence often linked to ease of consumption.
The next phase of research, funded by the European Union’s Horizon 2025 program, will assess long-term cardiovascular outcomes associated with magnesium bisglycinate use. Preliminary findings suggest a 15% reduction in systolic blood pressure among participants with prehypertension, though larger trials are needed to confirm these results.
For now, healthcare professionals advise patients to consult with their physicians before initiating magnesium supplementation, particularly for those with chronic conditions or on multiple medications. As Jungbunzlauer expands its product line, the focus remains on balancing innovation with evidence-based practice to address widespread nutritional deficiencies.
